Cite

HARVARD Citation

    Lüers, A. et al. (n.d.). 3119 P53 disruptive mutation is a negative predictive factor in EGFR M+ NSCLC treated with TKI. European journal of cancer. pp. S643-. [Online]. 
  
Back to record